Topical Interleukin-1 receptor antagonist therapy and corneal healing after photorefractive - PowerPoint Presentation

Slide1

Topical Interleukin-1 receptor antagonist therapy and corneal healing after photorefractive keratectomy in New Zealand White rabbits

Brett Davies, Capt, USAF, MC; Vasudha Panday, Maj, USAF, MC; Charles Reilly, Lt Col, USAF, MC ; Matthew Caldwell, Maj, USAF, MCWilford Hall Air Force Medical CenterSan Antonio, TX

The authors have no financial interest to discloseTopical IL-1ra provided by TheraKine, Inc.The conclusions do not necessarily reflect the views of the USAF or the DOD

ASCRS 2010, Boston, MA

Purpose

This is a randomized, blinded study designed to compare topical Interleukin-1 antagonist (IL-1ra) against standard steroid treatment following photorefractive keratectomy (PRK). Vs

Steroids

Glaucoma CataractsSecondary infectionDelayed wound healing

Interleukin-1

Methods

Outcome Measures

Time to re-epithelizationWeekly slit lamp exam for haze

Pentacam evaluation prior to and at weeks 1,2,3, and 7

Histologic

exam at week 7

Results

No difference in epithelial healing timeTime to re-

epithelization:

Results- Slit lamp exam

p=0.392p<0.005

p<0.005

p=0.536

Subjective Haze

Results-

Pentacam Haze

p<0.0001

Results-Histology

Steroids

2.5mg

1.25mg

0.25mg

Central Foam Layer

p = 0.725

Thickest Foam Layer

p = 0.997

Conclusions

Further studies needed to determine side effects of IL-1ra as well as response in human corneaIL-1ra does not increase epithelial healing timeNo difference in foam layer between treatment groupsSteroids significantly better than other groups on subjective haze analysis at weeks 4 and 5IL1-ra reduced objective haze (Pentacam

) similar to steroids at 1 month post opLower doses of IL1-ra reduced objective haze more than higher dose

References

Dinarello CA, Wolff SM. The role of interleukin-1 in disease. N Engl J Med 1993; 328: 106Le J, Vilcek J. Tumor necrosis factor and interleukin 1: cytokines with multiple overlapping biological activities. Lab Invest 1987; 56: 234.Kijlstra A. The role of cytokines in ocular inflammation. Br J Ophthalmol 1994; 78: 885Girard MT, Matsubara

M, Fini ME. Transforming growth factor-beta and interleukin-1 modulate metalloproteinase expression by corneal stromal cells. Invest Ophthalmol Vis Sci

1991; 32: 2441.

Yamada, J, Dana MR,

Sotozono

C, Kinoshita S. Local suppression of IL-1 by receptor antagonist in the rat model of corneal alkali injury. Experimental Eye Research2003; 76(2): 161-7.

Biswas

PS,

Banerjee

K,

Zheng

M, Rouse BT. Counteracting corneal

immunoinflammatory

lesion with interleukin-1 receptor antagonist protein. J

Leukoc

Biol. 2004; 76(4): 868-75

Netto

MV. Wilson SE. Corneal wound healing relevance to

wavefront

guided laser treatments. [Review] [58 refs] Ophthalmology Clinics of North America 2004; 17(2): 225-31

Kaji

Y. Yamashita H.

Oshika

T. Corneal wound healing after

excimer

laser keratectomy. [Review] [28 refs] Seminars in Ophthalmology 2003; 18(1): 11-6

Alio

JL. Perez-

Santonja JJ. Tervo T. Tabbara KF. Vesaluoma M. Smith RJ. Maddox B. Maloney RK. Postoperative inflammation, microbial complications, and wound healing following laser in situ keratomileusis

. [Review] [82 refs] Journal of Refractive Surgery 2000; 16(5): 523-38Wachtlin J. Langenbeck K. Schrunder S. Zhang EP. Hoffmann F.

Immunohistology of corneal wound healing after photorefractive keratectomy and laser in situ keratomileusis. Journal of Refractive Surgery 1999; 15(4): 451-8Kato T. Nakayasu

K. Hosoda Y. Watanabe Y. Kanai A. Corneal wound healing following laser in situ keratomileusis (LASIK): a histopathological study in rabbits. British Journal of Ophthalmology 1999; 83(11): 1302-5

Gan

, L.,

Hamberg-Nystrom

, H,

Fagerholm

, P, Van

Setten

, G.

Cellular proliferation and leukocyte infiltration in the rabbit cornea after photorefractive keratectomy.

Acta

Ophthalmologica

Scandinavica

. 79(5):488-492, October 2001